skip to main content


Title: Tau neutrinos in the next decade: from GeV to EeV
Abstract Tau neutrinos are the least studied particle in the standard model. This whitepaper discusses the current and expected upcoming status of tau neutrino physics with attention to the broad experimental and theoretical landscape spanning long-baseline, beam-dump, collider, and astrophysical experiments. This whitepaper was prepared as a part of the NuTau2021 Workshop.  more » « less
Award ID(s):
2033500 2111232
NSF-PAR ID:
10402966
Author(s) / Creator(s):
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; more » ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; « less
Date Published:
Journal Name:
Journal of Physics G: Nuclear and Particle Physics
Volume:
49
Issue:
11
ISSN:
0954-3899
Page Range / eLocation ID:
110501
Format(s):
Medium: X
Sponsoring Org:
National Science Foundation
More Like this
  1. Whitepaper for the 2023 NSAC Long Range Plan 
    more » « less
  2. Vishniac, E ; Muench, A (Ed.)
    Models for space weather forecasting will never be complete/valid without accounting for inter-hemispheric asymmetries in Earth’s magnetosphere, ionosphere and thermosphere. This whitepaper is a strategic vision for understanding these asymmetries from a global perspective of geospace research and space weather monitoring, including current states, future challenges, and potential solutions. 
    more » « less
  3. Proteins make up much of the machinery of cells and perform many roles that are essential for life. Some important proteins – known as intrinsically disordered proteins – lack any stable three-dimensional structure. One such protein, called tau, is best known for its ability to form tangles in the brain, and a buildup of these tangles is a hallmark of Alzheimer’s disease and many other dementias. Tau is also one of a number of proteins that can undergo a process called liquid-liquid phase separation: essentially, a solution of tau separates into a very dilute solution interspersed with droplets of a concentrated tau solution, similar to an oil-water mixture separating into a very watery solution with drops of oil. Understanding the conditions that lead to spontaneous liquid-liquid phase separation might give insight into how the tau tangles form. However, it was not known whether it is possible in principle for liquid-liquid phase separation of tau to occur in a living brain. Lin, McCarty et al. have now used an advanced computer simulation method together with experiments to map the conditions under which a solution containing tau undergoes liquid-liquid phase separation. Temperature as well as the concentrations of salt and the tau protein all influenced how easily tau droplets formed or dissolved, and the narrow range of conditions that encouraged droplet formation fell within the normal conditions found in the body, also known as “physiological conditions”. This suggested that tau droplets might form and dissolve easily in living systems, and possibly in the brain, depending on the precise physiological conditions. To explore this possibility further, tau protein was added to a dish containing living cells. As the map suggested, slightly adjusting temperature or protein concentrations caused tau droplets to form and dissolve, all while the cells remained alive. The map provided by this study may offer guides to researchers looking for liquid-liquid phase separation in the brain. If liquid-liquid phase separation of tau occurs in living brains, it may be important for determining whether and when damaging tau tangles emerge. For example, the high concentration of tau in droplets might speed up tangle formation. Ultimately, a better understanding of the conditions and mechanism for liquid-liquid phase separation of tau can help researchers understand the role of protein droplet formation in living systems. This may be a process that promotes, or possibly a regulatory mechanism that prevents, the formation of tau tangles associated with dementia. 
    more » « less
  4. Background: Tau assembly produces soluble oligomers and insoluble neurofibrillary tangles, which are neurotoxic to the brain and associated with Alzheimer’s and Parkinson’s diseases. Therefore, preventing tau aggregation is a promising therapy for those neurodegenerative disorders. Objective: The aim of this study was to develop a joint computational/cell-based oligomerization protocol for screening inhibitors of tau assembly. Methods: Virtual oligomerization inhibition (VOI) experiment using molecular dynamics simulation was performed to screen potential oligomerization inhibitors of PHF6 hexapeptide. Tau seeding assay, which is directly related to the outcome of therapeutic intervention, was carried out to confirm a ligand’s ability in inhibiting tau assembly formation. Results: Our protocol was tested on two known compounds, EGCG and Blarcamesine. EGCG inhibited both the aggregation of PHF6 peptide in VOI and tau assembly in tau seeding assay, while Blarcamesine was not a good inhibitor at the two tasks. We also pointed out that good binding affinity to tau aggregates is needed, but not sufficient for a ligand to become a good inhibitor of tau oligomerization. Conclusion: VOI goes beyond traditional computational inhibitor screening of amyloid aggregation by directly examining the inhibitory ability of a ligand to tau oligomerization. Comparing with the traditional biochemical assays, tau seeding activities in cells is a better indicator for the outcome of a therapeutic intervention. Our hybrid protocol has been successfully validated. It can effectively and efficiently identify the inhibitors of amyloid oligomerization/aggregation processes, thus, facilitate to the drug development of tau-related neurodegenerative diseases. 
    more » « less
  5. Cellular internalization and the spreading of misfolded tau have become increasingly important for elucidating the mechanism of Tau pathology involved in Alzheimer’s disease (AD). The low-density lipoprotein-related receptor 1 (LRP1) has been implicated in the internalization of fibrillar tau. In this work, we utilized homology modeling to model the Cluster 2 domain of LRP1 and determined that a 23-amino-acid sequence is involved in binding to paired helical filaments (PHF) of Tau. Fourteen short peptide segments derived from this ectodomain region were then designed and docked with PHF Tau. Molecular dynamics studies of the optimal peptides bound to PHF Tau demonstrated that the peptides formed critical contacts through Lys and Gln residues with Tau. Based on the computational results, flow cytometry, AFM, SPR analysis and CD studies were conducted to examine binding and cellular internalization. The results showed that the peptide sequence TauRP (1–14) (DNSDEENCES) was not only associated with fibrillar Tau but was also able to mitigate its cellular internalization in LRP1-expressed HEK-293 cells. Preliminary docking studies with Aβ (1–42) revealed that the peptides also bound to Aβ (1–42). While this study focused on the CCR2 domain of LRP1 to design peptide sequences to mitigate Tau internalization, the work can be extended to other domains of the LRP1 receptor or other receptors to examine if the cellular internalization of fibrillar Tau can be deterred. These findings show that short peptides derived from the LRP1 receptor can alter the internalization of its ligands. 
    more » « less